XML 38 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
THE COMPANY (Details Narrative)
 0 Months Ended
Oct. 02, 2011
Dec. 31, 2012
Dec. 31, 2011
Oct. 03, 2011
Jul. 29, 2011
Jul. 28, 2011
Dec. 31, 2010
Merger agreeement description with VitaMed completed the following required corporate actions: a reverse split of the Company's 16,575,209 issued and outstanding shares of Common Stock on a ratio of 1 for 100 (the "Reverse Split"). As a result of the Reverse Split, each share of Common Stock outstanding on July 28, 2011 (the "Record Date"), without any action on the part of the holder thereof, became one one-hundredth of a share of Common Stock. The Reverse Split decreased the number of outstanding shares of the Company's Common Stock by approximately 99% resulting in 165,856 shares outstanding after the Reverse Split. The effectuation of the Reverse Split did not result in a change in the relative equity position or voting power of the shareholders of the Company; an increase of our authorized shares of Common Stock to 250,000,000; a change in the name of the Company to TherapeuticsMD, Inc.; and an amendment to the Company's Long Term Incentive Compensation Plan to increase the authorized shares for issuance thereunder to 25,000,000.            
Reverse split description 1 for 100            
Common stock, shares outstanding   99,784,982 82,978,804 58,573,187 165,856 16,575,209 55,487,321
Common stock, shares authorized   250,000,000 250,000,000   250,000,000    
Shares authorized under Incentive Plan         25,000,000    
Shares exchanged, on a pro rata basis with VitaMed 70,000,000            
Shares issued in exchange for Units       58,407,331      
Former members of VitaMed ownership percentage in common stock       99.00%      
Company Options
              
Shares reserved for issuance in merger agreement       10,119,796      
Company Warrants
              
Shares reserved for issuance in merger agreement       1,472,916